A New Heart Finding Changes the EGPA Regimen: Biologic-First or Cyclophosphamide Now
A man with longstanding asthma and new eosinophilic granulomatosis with polyangiitis develops evidence of cardiac involvement mid-workup. The biologic era has genuinely reshaped how this disease gets treated — but not, the room is about to argue, for the specific presentation he just walked in with.
P.A., a 48-year-old high-school athletics coach, has had adult-onset asthma and chronic sinusitis for six years, managed reasonably well until the past two months, when he developed new numbness and weakness in his right foot that made it hard to keep pace running drills with his own team, along with a faint purple rash across both shins he assumed was from bruising equipment bags rather than anything medical.
The combination brought him in fast, and the workup moved fast too. Blood eosinophils came back at 6,200 cells/µL, nerve conduction studies confirmed mononeuritis multiplex in the affected foot, and skin biopsy of the rash showed leukocytoclastic vasculitis with tissue eosinophilia — eosinophilic granulomatosis with polyangiitis by any reasonable criteria, and ANCA came back negative, a pattern more often associated in this disease with cardiac rather than renal involvement. That association turned out not to be theoretical: cardiac MRI, ordered specifically because of the ANCA-negative result rather than any cardiac symptom he'd reported, showed new patchy myocardial late gadolinium enhancement consistent with eosinophilic myocarditis. He has no chest pain, no dyspnea, and an entirely normal ejection fraction on echocardiogram — the finding is real and organ-threatening by definition, but it is asymptomatic, discovered only because someone looked. That single word, organ-threatening, is what moves him: MIRRA, the trial behind mepolizumab's EGPA approval, enrolled relapsing or refractory disease and excluded anyone with organ-threatening EGPA in the three months before screening. He is newly diagnosed rather than relapsing, and organ-threatening as of this week — outside that population on both counts, and outside MANDARA's too, since it was built as a comparison within the same relapsing/refractory group.
Until two months ago he considered himself, in his own words, "in better shape than most of the kids I coach," with no cardiac history and no hypertension behind him. His wife was in the room when the MRI result came back and asked the question everyone in the workup had been quietly holding: how does a heart problem show up with no symptoms at all. The honest answer is that eosinophilic myocarditis often does exactly that until it doesn't, which is the entire reason the team looked for it in someone with no cardiac complaint in the first place.
Urgent multidisciplinary consultation, before induction therapy is chosen
The biologic era has genuinely changed how EGPA gets managed, and I don't want that progress lost in this conversation. Mepolizumab's approval came directly from the MIRRA trial showing real remission and steroid-sparing benefit, and benralizumab's more recent approval, from MANDARA, showed noninferiority to mepolizumab with a faster onset of eosinophil suppression — a real advantage if we're worried about ongoing eosinophil-mediated organ damage right now.
I'd weight the trial populations more heavily than the mechanism here. MIRRA specifically enrolled relapsing or refractory EGPA and largely excluded patients with severe, organ-threatening manifestations — new myocarditis, even asymptomatic, is exactly the kind of finding that population didn't include. The Five Factor Score has treated cardiac involvement as a marker of worse prognosis warranting more aggressive induction for decades — and I'd note the revised score keys on cardiac symptoms, which he doesn't have, so this is the original cardiomyopathy criterion being applied to imaging rather than a box he formally ticks, and that's precisely the situation in front of us: new-onset, organ-threatening disease, not relapsing symptomatic asthma needing steroid-sparing maintenance.
The benralizumab speed argument is a real consideration, but MANDARA was designed and powered as a noninferiority comparison to mepolizumab specifically in the same relapsing/refractory population MIRRA studied — it doesn't extend that population to cover new organ-threatening presentations any more than MIRRA did.
From where I sit, the finding itself is more informative than either trial. New myocardial involvement in EGPA, even asymptomatic with a preserved ejection fraction, is a recognized cause of sudden cardiac events, and cyclophosphamide-based induction has the longest track record for controlling that specific manifestation quickly. I'd want aggressive induction now, with cardiac monitoring alongside it, before considering whether a biologic has a role in maintenance once the acute threat is controlled.
This isn't a rejection of biologics for EGPA broadly — the allergist's point about their real, established role stands for exactly the population MIRRA and MANDARA actually studied. It's that a new cardiac finding moves him out of that population and into the group the older cyclophosphamide-based literature was built for.
Agreed: cyclophosphamide-based induction with high-dose glucocorticoids started today, cardiac monitoring arranged alongside it, and mepolizumab named explicitly as the maintenance-phase plan once induction achieves control.
Not agreed: how soon into the induction course to introduce mepolizumab as a steroid-sparing maintenance agent. The allergist would introduce it as soon as cardiac markers stabilize, to reduce cumulative steroid exposure sooner; the rheumatologist prefers waiting for a defined induction endpoint (typically three to six months) before adding a second agent, to keep the induction response cleanly attributable. Left for reassessment at the one-month cardiac recheck.